Puma Biotechnology

$11.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.42 (+3.86%) Today

$0.00 (0.00%) As of 9:33 PM UTC after-hours

Why Robinhood?

You can buy or sell PBYI and other stocks, options, and ETFs commission-free!

About PBYI

Puma Biotechnology Inc Common Stock, also called Puma Biotechnology, is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA. The listed name for PBYI is Puma Biotechnology Inc Common Stock.

CEO

Alan H. Auerbach

Employees

269

Headquarters

Los Angeles, California

Founded

2010

Market Cap

463.95M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

470.20K

High Today

$11.34

Low Today

$10.82

Open Price

$10.82

Volume

212.27K

52 Week High

$14.14

52 Week Low

$5.50

PBYI News

BenzingaFeb 20

Tigerlily Foundation Launches a New Web Series, BREATHE Tv on Facebook Live

Stone Ridge, VA, February 20, 2021 --(PR.com)-- Tigerlily Foundation in partnership with Puma Biotechnology, Inc. is excited to announce the launch of BREATHE T

Analyst Ratings

10%

of 10 ratings

Buy

10%

Hold

50%

Sell

40%

PBYI Earnings

-$1.00

-$0.55

-$0.10

$0.35

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$0.29 per share

Actual

Available Feb 25, After Hours

Preview Earnings Call